Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Amyloid Fibrils

Amyloid Fibrils

Amyloid Fibrils

Amyloid Fibrils

Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...

Nephrotic Syndrome I : Introduction

Nephrotic Syndrome I : Introduction

Nephrotic Syndrome is a chronic kidney disorder defined by clinical findings such as severe proteinuria, hypoalbuminemia, hyperlipidemia, and edema. These symptoms result from damage to the glomeruli, the kidney’s filtering units, increasing their permeability to proteins.Definition and Meaning:Proteinuria, defined as the loss of more than 3.5 grams of protein per day in adults, is a crucial feature of nephrotic syndrome. This condition is often accompanied by edema, the accumulation of...

Cardiomyopathy IV: Restrictive Cardiomyopathy

Cardiomyopathy IV: Restrictive Cardiomyopathy

Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Effects of Acoramidis on Kidney Function in Transthyretin Amyloid Cardiomyopathy.

Circulation. Heart failure·2026

Same author

Differential Transthyretin Stabilization in Patients With Wild Type and Variant Transthyretin Amyloidosis.

JACC. CardioOncology·2026

Same author

Outpatient worsening heart failure in transthyretin amyloid cardiomyopathy: Findings from ATTRibute-CM.

European journal of heart failure·2026

Same author

Baseline characteristics of patients with transthyretin amyloidosis with cardiomyopathy in the CARDIO-TTRansform trial of eplontersen.

European journal of heart failure·2026

Same author

Efficacy and Safety of Anselamimab in Immunoglobulin Light Chain Amyloidosis: Results From the Randomized CARES Trials.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026

Same author

Vutrisiran-Mediated Knockdown of Transthyretin in Patients with ATTR Amyloidosis.

Clinical pharmacokinetics·2026

Same journal

Rethinking anticoagulation intensity during extracorporeal membrane oxygenation.

Lancet (London, England)·2026

Same journal

Standard-dose unfractionated heparin versus low-dose unfractionated heparin and low-molecular-weight heparin in extracorporeal life support (RATE): an open-label, randomised, non-inferiority trial.

Lancet (London, England)·2026

Same journal

Inherited retinal degenerations: clinical phenotypes and emerging therapies.

Lancet (London, England)·2026

Same journal

Documenting hospice care.

Lancet (London, England)·2026

Same journal

After the wood chipper.

Lancet (London, England)·2026

Same journal

Assisted dying and the silencing of medicine's next generation.

Lancet (London, England)·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Mar 28, 2026

Genetic Analysis of Hereditary Transthyretin Ala97Ser Related Amyloidosis

Genetic Analysis of Hereditary Transthyretin Ala97Ser Related Amyloidosis

Published on: June 9, 2018

Systemic amyloidosis.

Ashutosh D Wechalekar¹, Julian D Gillmore¹, Philip N Hawkins¹

¹National Amyloidosis Centre, University College London (Royal Free Campus), London, UK.

Lancet (London, England)

|January 1, 2016

Summary

This summary is machine-generated.

Systemic amyloidoses, caused by protein fibril deposits, are increasingly diagnosed. Advances in diagnosis and novel treatments offer hope, but early detection remains crucial for better outcomes in these rare diseases.

More Related Videos

Performing and Processing FNA of Anterior Fat Pad for Amyloid

Performing and Processing FNA of Anterior Fat Pad for Amyloid

Published on: October 30, 2010

Rapid Generation of Amyloid from Native Proteins In vitro

Rapid Generation of Amyloid from Native Proteins In vitro

Published on: December 5, 2013

Related Experiment Videos

Last Updated: Mar 28, 2026

Genetic Analysis of Hereditary Transthyretin Ala97Ser Related Amyloidosis

Genetic Analysis of Hereditary Transthyretin Ala97Ser Related Amyloidosis

Published on: June 9, 2018

Performing and Processing FNA of Anterior Fat Pad for Amyloid

Performing and Processing FNA of Anterior Fat Pad for Amyloid

Published on: October 30, 2010

Rapid Generation of Amyloid from Native Proteins In vitro

Rapid Generation of Amyloid from Native Proteins In vitro

Published on: December 5, 2013

Area of Science:

Rare diseases
Protein misfolding disorders
Systemic amyloidoses

Background:

Systemic amyloidoses result from protein fibril deposition in tissues.
Systemic light chain (AL) amyloidosis is most common, with wild-type transthyretin cardiac amyloidosis (ATTRwt) rising.
Epidemiology, diagnosis, and treatment of these rare conditions are evolving.

Purpose of the Study:

To review current epidemiology of systemic amyloidoses.
To discuss advancements in diagnostic approaches.
To highlight progress in therapeutic strategies.

Main Methods:

Improved amyloid fibril typing using laser capture and mass spectrometry.
Enhanced cardiac amyloidosis evaluation with cardiac MRI and bone scintigraphy tracers.
Review of novel chemotherapy agents and emerging therapeutic targets.

Main Results:

Survival in AL amyloidosis has improved with new chemotherapy.
Cardiac amyloidosis diagnosis is more accurate with advanced imaging.
Early diagnosis remains a significant challenge despite treatment advances.

Conclusions:

Novel diagnostic tools improve amyloidosis detection and typing.
Emerging therapies like RNA inhibitors and immunotherapies show promise.
Transforming outcomes requires addressing challenges in advanced disease and early diagnosis.